TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review published in Oncoscience on September 30, 2026, surveys how extracellular vesicles carry signals involved in normal cell function, aging and cancer. The authors describe overlapping features in vesicles from senescent and tumor cells, while stressing that their effects depend on the cells and environment involved.
A review published in Oncoscience on September 30, 2026, examines how extracellular vesicles—particles that carry molecular signals between cells—are involved in healthy biological processes, aging and cancer. The authors, led by Ethan Umeris and corresponding author Igor Kovalchuk of the University of Lethbridge, describe similarities and differences in signals from aging and cancer cells that researchers are investigating for possible biomarkers and therapeutic approaches.
Extracellular vesicles, or EVs, transport proteins, lipids and genetic material between cells. The review describes their roles in processes such as tissue repair, immune regulation and cellular balance. Their contents can change with stress, inflammation or disease, potentially affecting neighboring cells. The review focuses particularly on exosomes, a well-studied type of EV whose effects vary according to their source and surroundings.
In aging tissues, the authors discuss exosomes released by senescent cells. These may contain inflammatory molecules and regulatory microRNAs that influence gene expression in nearby cells. The review links such signaling to processes associated with aging, including chronic inflammation and impaired tissue repair; it does not establish that exosomes alone cause these changes.
For cancer, the review describes research on tumor-derived exosomes that may help cancer cells survive and alter surrounding tissue. The studies discussed connect these vesicles with immune evasion, blood-vessel formation, metastasis and treatment resistance. These are findings summarized from existing research, not evidence that every tumor releases the same cargo or that the particles have identical effects in every setting.
Why EV Signals Matter to Research
The review brings together research on a possible point of connection between aging biology and cancer progression: both senescent and tumor cells can release vesicles containing inflammatory signals, stress-related proteins and genetic material. Comparing what these vesicles carry—and how recipient cells respond—could help researchers distinguish disease-related changes from broader effects of aging.
The authors point to potential clinical uses, but these remain research prospects. Because vesicle contents may reflect the condition of the cells that release them, EVs are being studied as possible biomarkers of aging and disease. Their capacity to transport biological molecules has also drawn interest for targeted drug delivery. The review does not report a validated diagnostic test or an approved EV-based treatment; further work would be needed to establish whether these approaches are useful and safe in clinical care.
For readers, the distinction between a research possibility and a current medical tool matters. The review is a synthesis of scientific work, not a report that a new test or therapy is ready for patients. Its relevance lies in organizing questions that may guide future studies of cell communication and disease.
Products Worth Considering
Weber Original Kettle Charcoal Grill, 22-Inch, Black
Orbit B-hyve XR 8-Zone Indoor/Outdoor Smart Sprinkler Controller
Greenworks 48V (2 × 24V) 20-Inch Brushless Cordless Push Lawn Mower with Two 4.0Ah Batteries and Dual-Port Charger
As an affiliate, we earn on qualifying purchases.
From Cell Messages to Disease
The article, titled “Extracellular vesicles in health, aging and disease,” was published in Volume 13 of Oncoscience. First author Ethan Umeris and corresponding author Igor Kovalchuk are affiliated with the Department of Biological Sciences at the University of Lethbridge. News-Medical reported on the review on November 6, 2026.
EVs are a broad group of particles released by cells; exosomes are one type discussed in the review. Their cargo can carry information between cells, but a vesicle’s effects depend on its contents, the cell that released it and the receiving tissue. That dependence is central to the authors’ comparison: shared molecular features do not mean identical biological outcomes in aging and cancer.
The review’s central argument is that studying both overlap and divergence may help researchers identify signals specific to particular conditions. It draws on existing research rather than reporting a single new experiment or clinical trial.
““Thus, it is important to understand both the overlapping and divergent cargo of senescence-associated and tumor-derived exosomes to identify disease-specific biomarkers and to design targeted therapeutic treatments.””
— Ethan Umeris, Igor Kovalchuk and co-authors, as quoted in the review
Questions Before Clinical Use
The review does not establish whether EV-based biomarkers can reliably distinguish aging from specific diseases in patients, or how well such tests might perform across different tissues and populations. It also does not show that therapies targeting vesicles, or using them to deliver drugs, are ready for clinical use.
Further research is needed to clarify which molecular cargo is distinctive to senescent cells versus tumors, how those signals affect nearby cells, and how results from different experimental settings translate to people. The source material does not specify a clinical development timeline or report a trial testing an EV-based diagnostic or treatment.
Research Needed to Test Applications
The next steps described by the review are scientific rather than a scheduled clinical milestone: researchers need to compare senescence-associated and tumor-derived exosome cargo, identify signals linked to particular diseases, and test how these signals affect recipient cells. Work on possible biomarkers and drug delivery would then need to establish performance and safety before any clinical application could be assessed.
The review itself presents a synthesis of current research and does not announce a new trial, diagnostic release or treatment. Whether the proposed applications advance will depend on further studies; no specific next publication or trial date was provided.
Key Questions
What are extracellular vesicles?
Extracellular vesicles are particles released by cells that can transport proteins, lipids and genetic material to other cells. The review focuses particularly on exosomes, one type of EV.
What does the review say about aging and cancer?
It describes some overlapping signals in vesicles from senescent and cancer cells, including inflammatory and stress-related components. It also emphasizes that the vesicles’ effects depend on their source and environment.
Are EVs already a cancer test or treatment?
The review discusses EVs as possible future biomarkers and drug-delivery tools. It does not report a validated diagnostic test or an approved EV-based cancer treatment.
Who wrote the review and when was it published?
First author Ethan Umeris and corresponding author Igor Kovalchuk, affiliated with the University of Lethbridge, authored the review. It appeared in Oncoscience on September 30, 2026.
Source: news-medical.net
